期刊文献+

血压对老年自发性高血压大鼠腹侧前列腺增殖的影响 被引量:5

Effect of blood pressure on ventral prostate proliferation in aging spontaneously hypertensive rat
原文传递
导出
摘要 目的探讨血压变化对老龄自发性高血压大鼠(SHR)腹侧前列腺增殖的影响。方法SHR给药组在出生1个月后即开始按每天100mg/kg给予喂食卡托普利,并设SHR对照组和正常血压对照组(WKY),每组各5只。间接测量尾动脉收缩压(SBP)。分别在6月龄时、12月龄时处死动物,计算腹侧前列腺重量月增长率和前列腺指数,常规病理检查。结果SHR对照组SBP随月龄增加而上升,在SHR给药组,SBP经大剂量卡托普利治疗后得以控制,但仍高于WKY组。1月龄时,SHR和WKY腹侧前列腺重量平均值分别为186.2mg和130.0mg,6月龄时SHR给药组、SHR对照组及WKY组前列腺重量月增长率(mg/月)分别为25.63±3.59、42.76±14.4和48.26±4.5,12月龄时分别为16.53±1.43、23.32±2.15和28.61±3.99,6月龄或12月龄时SHR给药组前列腺重量月增长率低于同龄SHR对照组及WKY组(P<0.05)。6月龄时SHR给药组、SHR对照组及WKY组前列腺指数(mg/g)分别为1.01±0.09、1.12±0.14和0.93±0.07,12月龄时分别为0.95±0.06、1.11±0.05和0.96±0.09;12月龄的老年SHR给药组的指数明显低于同龄SHR对照组(P<0.05),与同龄WKY组接近(P>0.05);而SHR对照组指数在成年或老年期均高于WKY组(P<0.05)。结论高血压促进SHR BPH的发生发展,早期给予大剂量卡托普利控制血压可延缓SHR发生BPH的进程。 Objective To evaluate the effect of blood pressure on ventral prostate proliferation in aging spontaneously hypertensive rats (SHR). Methods In the SHRs treatment group, one-month-old rats were treated with captopril (100mg/kg × d^-1), and age and weight matched untreated SHR and normotensive Wistar Kyoto(WKY) rats served as controls. There were 5 rats in each group. After measurement of systolic blood pressure (SBP) and body weight, all rats were killed at 6 months or 12 months old. The monthly growth rate of prostate weight and prostate index were calculated. Conventional pathological analysis was performed. Results SBP increased with age in SHR control group. SBP of SHR treatment group with high-dose captopril treatment was controlled, but it was still higher than that of the WKY group. The monthly growth rate of rat prostate weight (mg/month) at 6-month-old in SHR treatment group, SHR control group and WKY group was 25.63±3.59, 42.76±14.4 and 48.26±4.5 respectively, at 12 months was16.53±1.43, 23.32±2.15, 28.61±3.99 respectively. The monthly growth rate of rats at 6 or 12-month-old in SHR treatment group was lower than that of the SHR control group and WKY group (P 〈0.05). The prostate index(mg/g)of rats at 6-month-old in SHR treatment group, SHR control group and WKY group was 1.01±0.09, 1.12±0.14 and 0.93±0.07 respectively, at 12 months was 0.95±0.06, 1.11±0.05, 0.96±0.09 respectively. The prostate index of rats at 12-month-old in SHR treatment group was significantly lower than that of the SHR control group (P 〈0.05) and was similar with that of the WKY group (P〉 0.05), while the prostate index of the SHR control group in adult or old age were all higher than that of WKY group (P 〈0.05). Conclusion High blood pressure might promote BPH development in SHR rats, and the control of blood pressure by high-dose captopril might delay the development of BPH in SHR.
出处 《中国男科学杂志》 CAS CSCD 2009年第7期27-29,32,共4页 Chinese Journal of Andrology
关键词 血压 大鼠 近交SHR 前列腺增生 blood pressure rats, inbred SHR prostatic hyperplasia
  • 相关文献

参考文献11

  • 1Golomb E,Rosenzweig N,Eilam R,et al.Spontaneous.hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats.JAndro12000;21(1):58-64. 被引量:1
  • 2Matityahou A,Rosenzweig N,Golomb E.Rapid proliferation of prostatic epithelial cells in spontaneously hypertensive rats:a model of spontaneous hypertension and prostate hyperplasia.J Androl 2003;24(2):263-269. 被引量:1
  • 3Boyle P,Napalkov P.The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension.Stand J Uroi Nephrol Suppl 1995;168:7-12. 被引量:1
  • 4史新竹,时景璞,宁夏,郑力国,吴作艳.农村老年人高血压与前列腺增生的研究[J].中国公共卫生,2003,19(8):942-943. 被引量:35
  • 5汪婷婷,毛广运,蒋善群,徐希平.农村高血压人群良性前列腺增生影响因素分析[J].中国公共卫生,2008,24(2):191-192. 被引量:6
  • 6郭利君,张祥华,李培军,那彦群.良性前列腺增生与原发性高血压的相关性研究[J].中华外科杂志,2005,43(2):108-111. 被引量:59
  • 7Michel MC,Heemann U,Schumacher H,et al.Association of hypertension with symptoms of benign prostatic hyperplasia.J Urol 2004;172(4 Pt 1):1390-1393. 被引量:1
  • 8Hammarsten J,Hogstedt B.Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.Eur Urol 2001;39(9):151-158. 被引量:1
  • 9Meigs JB,Mohr B,Barry M J,et al.Risk factors for clinical benign prostatic hyperplasia in a communitybased population of healthy aging men.J Clin Epidemiol 2001;54(9):935-944. 被引量:1
  • 10Parsons KJ.Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms:new approaches to old problems.J Uro12007;178(2):395-401. 被引量:1

二级参考文献27

  • 1张骞,彭靖,张祥华,郭应禄,金杰.环氧化酶-2对大鼠前列腺增生的影响及作用机理研究[J].中华泌尿外科杂志,2005,26(7):468-471. 被引量:7
  • 2顾方六,山岗志,王通生,薛兆英.北京城乡良性前列腺增生发病的差异[J].中华泌尿外科杂志,1995,16(7):387-390. 被引量:61
  • 3林凯臣,王华伍,王苹,王泽敏,陈锐平,蔡伯基,王建才.性活动与前列腺增生症的相关研究[J].实用全科医学,2007,5(1):46-47. 被引量:6
  • 4Maruenda J, Bhatnagar V, Lowenthal DT. HyPertension in the elderly with coexisting benign prostatic hyperplasia. Urology, 1999, 53(Suppl 3A):7-12. 被引量:1
  • 5Hammarsten J, Hogstedt B, Holthuis N, et al. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis, 1998, 1:157-162. 被引量:1
  • 6Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol,2001, 39:151-158. 被引量:1
  • 7Nicolas Torralba JA, Tornero Ruiz J, Banon Perez V, et al. Relation between hypertension and clinical cases of benign prostatic hyperplasia. Arch Esp Urol,2003,56:355-358. 被引量:1
  • 8Golomb E, Rosenzweig N, Eilam R, et al. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl, 2000,21:58-64. 被引量:1
  • 9Nassis L, Frauman AG, Ohishi M, et al. Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia. J Pathol,2001,195 :571-579. 被引量:1
  • 10Dinh DT, Frauman AG, Somers GR, et al. Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin Ⅱ and reduced AT1 receptor expression in benign prostatic hyperplasia. J Pathol,2002,196:213-219. 被引量:1

共引文献81

同被引文献51

引证文献5

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部